May 14th 2024
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Combining Immune & Targeted Therapies in Melanoma: A Paradigm for Other Tumor Types?
June 6th 2014The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.
Non-Melanoma Skin Cancers: Reviewed Abstracts in Basal Cell and Merkel Cell Carcinoma
June 4th 2014Multiple abstracts on melanoma and skin cancer were reviewed at the ASCO Annual Meeting, with a focus on new treatment approaches in non-melanoma skin cancers, particularly basal cell carcinoma and Merkel cell carcinoma.
ONS 2014: Using Viruses to Fight Cancer
May 9th 2014Oncolytic viruses are receiving more attention these days as a form of cancer treatment, and have shown promise in clinical trials. These viruses are thought not only to cause direct destruction of the tumor cells, but also to stimulate a patient's immune response.
Sentinel-Node Biopsy Reduced Recurrence, Increased Melanoma-Specific Survival
February 20th 2014Sentinel-node biopsy for patients with intermediate-thickness melanomas increased disease-free survival and, in patients positive for nodal metastases, disease-specific survival, according to the final data from the MSLT-I study.
Targeted Intervention Decreased Melanoma Risk, Increased Early Prevention
February 7th 2014A new study found that a targeted screening and education strategy aimed at patients at high-risk for melanoma favorably affected behaviors that may reduce melanoma risk compared with a standard information-based campaign.